ADMA Biologics (ADMA) vs Harmony Biosciences (HRMY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Harmony Biosciences (HRMY) has outperformed ADMA Biologics (ADMA) over the past year, gaining 49.1% versus a loss of 27.5%. Over five years, ADMA leads with a +821.8% price change compared with +0.5% for HRMY. ADMA Biologics is the larger company by market cap ($2.31 billion vs $2.31 billion), about 1.0 times the size.
On valuation, Harmony Biosciences trades at a lower forward P/E (5.7x vs 11.0x for ADMA Biologics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | HRMY |
|---|---|---|
| Share price | $10.33 | $39.60 |
| Market cap | $2.31B | $2.31B |
| 1-day change | +1.87% | +0.66% |
| YTD return | -44.41% | +5.83% |
| 1-year return | -27.52% | +49.10% |
| 5-year return | +821.82% | +0.51% |
| P/E ratio (TTM) | 14.76 | 12.77 |
| Forward P/E | 10.95 | 5.65 |
| EPS (TTM) | $0.70 | $3.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.46 | $43.49 |
| 52-week low | $7.21 | $25.52 |
| Distance from 52-week high | -49.51% | -8.94% |
| Analyst consensus | none | buy |
| Avg. price target upside | +64.57% | +20.30% |
| Average volume | 2.63M | 892.55K |
| Shares outstanding | 223.98M | 58.24M |
| Employees | 640 | 293 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HRMY has outperformed ADMA by 76.6 percentage points over the past year.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
ADMA vs HRMY FAQ
Which is bigger, ADMA Biologics or Harmony Biosciences?
ADMA Biologics (ADMA) is larger, with a market capitalization of $2.31B compared with $2.31B for Harmony Biosciences (HRMY).
Which stock has performed better over the past year, ADMA or HRMY?
HRMY returned +49.10% over the past 12 months, compared with -27.52% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ADMA or HRMY?
HRMY has the lower trailing P/E at 12.8, versus 14.8 for ADMA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are ADMA Biologics and Harmony Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for ADMA Biologics and Biotechnology: Pharmaceutical Preparations for Harmony Biosciences.